了解HIV特异性T细胞对免疫检查点封锁的反应:我们可以从癌症免疫治疗中学到什么?
Céline Gubser1,2, Daniel E Kaufmann2
1Centre Hospitalier Univeristaire Vaudois, Epalinges.
Current opinion in HIV and AIDS
|July 19, 2025
概括
免疫检查点封锁 (ICB) 显示了增强HIV特异性T细胞反应的前景,从癌症免疫治疗中吸取教训. 需要进一步的研究和临床试验来探索ICB.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 在实现长期强有力的免疫反应以控制艾滋病毒方面存在持续的挑战.
- 癌症免疫疗法为免疫检查点阻塞 (ICB) 策略提供了宝贵的见解.
- 了解HIV特异性T细胞耗尽和其他因素对于治疗疗效至关重要.
研究的目的:
- 检查ICB在增强HIV特异性T细胞反应方面的潜力.
- 为了利用癌症免疫疗法的见解,为新的艾滋病毒治疗策略提供帮助.
- 讨论改善艾滋病毒治疗结果和推进功能治疗的创新方法.
主要方法:
- 关于ICB在癌症免疫治疗中的现有文献的审查及其对HIV的应用.
- 分析影响艾滋病毒背景下ICB成功的因素,包括T细胞耗尽,干细胞,T细胞受体克隆替代和抗原负载.
- 探索新的ICB疗法和工程方法.
主要成果:
- ICB策略超越PD-1和CTLA-4,新的癌症疗法显示出对HIV的潜力.
- 特定于艾滋病毒的T细胞耗尽,干细胞,T细胞受体克隆替代和抗原负载是ICB疗效的关键决定因素.
- 这些因素的复杂性需要研究改善艾滋病毒治疗的创新策略.
结论:
- ICB显示出HIV治愈策略的有前途潜力,但需要在艾滋病毒感染者 (PWH) 中进行进一步的临床试验调查.
- 未来的研究应该专注于新的免疫检查点目标,双特异性抗体,毒性最小化和生物标志物识别,以有效的ICB反应.
- 推进ICB是实现持久艾滋病毒控制的关键.
相关概念视频
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Cytotoxic T Cells-mediated Immune Response
2.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.2K
T Cell Activation and Clonal Selection
5.1K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
516
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
516


